Complete and lasting healing of bone melanoma metastasis after hyperthermic limb perfusion.
暂无分享,去创建一个
D. Nitti | C. Rossi | V. Sileni | J. Pigozzo | C. De Rossi | V. C. Sileni
[1] R. Greil,et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zoledronic acid, in premenopausal women with hormone-responsive, stage I and II breast cancer: First efficacy results from ABCSG-12. , 2008 .
[2] M. Caraglia,et al. Repeated Intermittent Low-Dose Therapy with Zoledronic Acid Induces an Early, Sustained, and Long-Lasting Decrease of Peripheral Vascular Endothelial Growth Factor Levels in Cancer Patients , 2007, Clinical Cancer Research.
[3] Rong-Sen Yang,et al. Rare clinical experiences for surgical treatment of melanoma with osseous metastases in Taiwan , 2007, BMC musculoskeletal disorders.
[4] R. Essner,et al. The role of surgery in treatment of stage IV melanoma , 2006, Journal of surgical oncology.
[5] J. Marsden,et al. Palliation of skeletal melanoma metastases with isolated limb perfusion chemotherapy. , 2006, Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.].
[6] J. Mckinnon. Palliation by perfusion: Is it worth it? , 2005, Journal of surgical oncology.
[7] A. Eggermont,et al. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients , 2005, Journal of surgical oncology.
[8] Michael B Atkins,et al. Management of cutaneous melanoma. , 2004, The New England journal of medicine.
[9] C. Riebeling,et al. Nitrogen-containing bisphosphonates inhibit cell cycle progression in human melanoma cells , 2004, British Journal of Cancer.
[10] A. Eggermont,et al. Prognostic factors for survival after isolated limb perfusion for malignant melanoma. , 2003, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[11] G. Bieler,et al. Zoledronate Sensitizes Endothelial Cells to Tumor Necrosis Factor-induced Programmed Cell Death , 2003, Journal of Biological Chemistry.
[12] G. Avvisati,et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[13] L. Devy,et al. Novel Antiangiogenic Effects of the Bisphosphonate Compound Zoledronic Acid , 2002, Journal of Pharmacology and Experimental Therapeutics.
[14] R. Mirimanoff,et al. Limb salvage by neoadjuvant isolated perfusion with TNFalpha and melphalan for non-resectable soft tissue sarcoma of the extremities. , 2000, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[15] A. V. van Geel,et al. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan for unresectable bone sarcomas of the lower extremity. , 1999, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[16] C. Perez,et al. Bone metastasis: review and critical analysis of random allocation trials of local field treatment. , 1999, International journal of radiation oncology, biology, physics.
[17] H. Schwartz,et al. Heterogeneous Survival Rates for Isolated Skeletal Metastases From Melanoma , 1996, Clinical orthopaedics and related research.
[18] I. Tannock,et al. Reflections on medical oncology: 25 years of clinical trials--where have we come and where are we going? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] A. Avilés,et al. Antitumor effect of zoledronic acid in previously untreated patients with multiple myeloma , 2007, Medical oncology.